hyperphosphataemia in chronic renal failure
Endocrinology · 2007–2019
2decisions
2medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| calcium carbonate Treatment of hyperphosphataemia associated with chronic renal failure. | Mar 2019 | Recommended | no section in document |
| lanthanum carbonate hydrate Treatment of hyperphosphataemia in adult patients with chronic renal failure on dialysis whose serum calcium levels are at least 2.60 mmol/L. | Mar 2007 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.